Norris Perne & French LLP Biomarin Pharmaceutical Inc Transaction History
Norris Perne & French LLP
- $1.36 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding BMRN
# of Institutions
638Shares Held
178MCall Options Held
2.01MPut Options Held
1.28M-
Black Rock Inc. New York, NY22.7MShares$1.47 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.3MShares$1.25 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.9MShares$1.22 Billion0.99% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$899 Million0.59% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.5MShares$679 Million0.16% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...